Speake Lab


Our group is interested in advancing clinical research – especially in type 1 diabetes, but also in the context of other immune-mediated diseases.

We focus on development and utilization of rigorous analytical methods to identify immune features associated with clinical outcomes, including progression of disease and response to therapy. We also seek to implement cutting-edge clinical trial designs, including use of short-term interventions with mechanistic outcomes and novel considerations of trial outcome measures.

With Drs. Lord and Smithmyer, Dr. Speake oversees BRI’s biorepositories. Her group collaborates with other academic researchers worldwide and facilitates collaborations with biotech and pharma companies. She also oversees BRI’s Clinical Core Laboratory, which is responsible for sample processing and storage for the hundreds of thousands of samples currently stored in the BRI biorepository.

Cate Speake
Research Assistant Member

Cate Speake, PhD

Research Assistant Member; Principal Investigator; Scientific Director, Interventional Immunology
View Full Bio

Lab Members

Christine Bender

Christine Bender, PhD

Postdoctoral Research Associate, Long & Speake Lab
View Bio
Linda Dement

Linda Dement

Grant & Finance Program Manager, Grants and Contracts and Center for Interventional Immunology
Rachel Hartley

Rachel Hartley

Project Manager, Center for Interventional Immunology
Pamela Miranda

Pamela Miranda

Research Technician, Center for Interventional Immunology
Thien Son Nguyen

Thien-Son Nguyen

Manager, Center for Interventional Immunology
Quyen Pham

Quyen Pham

Lab Technician, Center for Interventional Immunology
Sarah Robinson

Sarah Robinson

Administrative Assistant, Center for Interventional Immunology
Jessica Sarrat

Jessica Sarratt

Lab Technician, Center for Interventional Immunology
Megan Smithmyer

Megan Smithmyer, PhD

Staff Scientist, Center for Interventional Immunology
View Bio
Cameron Wellman

Cameron Willman

Research Technician, Center for Interventional Immunology

Research Projects

Speake Research Project Preview - TrialNet Pathway to Prevention

Understanding Progression of T1D

Type 1 Diabetes TrialNet provides rich data about people at risk for T1D. We analyze this data to help understand T1D risk, to better understand the process of T1D progression, and to help inform decisions around monitoring schedules for at risk patients.
View Project
Speake Research Project Preview - Sound Life Project

The Sound Life Project

The Sound Life Project is an investigation of the immune systems of adults without chronic diseases. Understanding the immune system in this context can help us understand why healthy people respond differently to vaccinations or infections.
View Project
Speake Research Project Preview - Rigor and Reproducibility

Rigor and Reproducibility in T1D Biomarker Research

Many potential biomarkers have been suggested in T1D, but translating them from discovery efforts to utility in clinical settings has been a challenge.  We focus on applying techniques to improve study design, data analysis, and technical reproducibility of assays. 
View Project

Related Stories

Blog Main Mikaela Horse Editorial
September 25, 2023

Participants Like Mikaela Fuel Research Advances

Participating in a clinical trial for type 1 diabetes (T1D) was easy for 9-year-old Mikaela. “Everyone was really nice. I just had to drink a milkshake with some medicine in it and get an IV.
Read Article
Feature - Clinical Research Subject Blue
September 19, 2023

An Insider's Look Into Clinical Trials at BRI

Before medicines become widely available, they have to be rigorously tested — first in the lab, then in people through clinical trials.
Read Article
Blog Main James Lab T1D Beta Stem Cells
June 30, 2023

To Belgium and Back Again to Study Beta Cells

BRI researchers are working to develop a groundbreaking new approach to treat type 1 diabetes (T1D). They aim to turn T cells that cause T1D into regulatory T cells (Tregs) that protect you from T1D.
Read Article


News icon

Monitoring T cells may allow prevention of type 1 diabetes

Read More ➡
Science in Seattle Logo

Science in Seattle: Characterizing T Cell Responses to Enzymatically Modified Beta Cell Neo-Epitopes

Read the publication ➡
Science in Seattle Logo

Science in Seattle: IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function

Read the Publication ➡